FrancophonIA/ELRC3.0 huggingface dataset:
English: The most common signs and symptoms of local infusion reactions were: redness at the injection site, itching, and rash.
Croatian: Najčešći znakovi i simptomi lokalne infuzijske reakcije bili su: Crvenilo na mjestu injekcije, svrbež i osip.
English: Grounds recommending the variation to the terms of the Marketing Authorisation
Croatian: Razlozi za preporuku izmjene uvjeta odobrenja za stavljanje lijeka u promet
English: For storage conditions after dilution of the medicinal product, see section 6.3.
Croatian: Uvjete čuvanja nakon razrjeđivanja, vidjeti u dijelu 6.3.
English: KRYSTEXXA 8 mg concentrate for solution for infusion pegloticase
Croatian: KRYSTEXXA 8 mg koncentrat za otopinu za infuziju peglotikaza
English: Package Leaflet: Information for the user KRYSTEXXA 8 mg concentrate for solution for infusion
Croatian: Uputa o lijeku: Informacije za korisnika KRYSTEXXA 8 mg koncentrat za otopinu za infuziju peglotikaza
English: • 1 ml of KRYSTEXXA should be injected into a single 250 ml bag of sodium chloride 4.5 mg/ml (0.45%) or 9 mg/ml (0.9%) solution for injection for infusion.
Croatian: • 1 ml lijeka KRYSTEXXA treba injicirati u pojedinačnu vrećicu od 250 ml otopine za injekciju ili infuziju koja sadrži 4,5 mg/ml (0,45%) ili 9 mg/ml (0,9%) natrijevog klorida.
English: • 1 ml of KRYSTEXXA should be injected into a single 250 ml bag of sodium chloride 4.5 mg/ml (0.45%) or 9 mg/ml (0.9%) solution for injection or infusion.
Croatian: • 1 ml lijeka KRYSTEXXA treba injicirati u pojedinačnu vrećicu od 250 ml otopine za injekciju ili infuziju koja sadrži 4,5 mg/ml (0,45%) ili 9 mg/ml (0,9%) natrijevog klorida .
English: From the nonclinical studies, the elimination of pegloticase is via renal/urinary excretion.
Croatian: U nekliničkim ispitivanjima potvrđeno je da se peglotikaza eliminira putem bubrega/mokraće.
English: Annex IV Scientific conclusions and grounds recommending the variation to the terms of the Marketing Authorisation
Croatian: Znanstveni zaključci i razlozi za preporuku izmjene uvjeta odobrenja za stavljanje lijeka u
English: Retreatment with KRYSTEXXA
Croatian: Ponovno liječenje lijekom KRYSTEXXA
English: How much KRYSTEXXA is given
Croatian: Koliko se lijeka KRYSTEXXA primjenjuje
English: The Pain scores using a visual analogue scale were 44.2 at baseline vs. 28.4 at Week 25 in patients treated with pegloticase 8 mg every 2 weeks compared to 53.9 vs. 57.2 in the placebo group (p≤0.001).
Croatian: Rezultati za bol primjenom vizualne analogne ljestvice bili su 44,2 na početku naspram 28,4 u 25. tjednu u bolesnika liječenih peglotikazom 8 mg svaka dva tjedna u usporedbi s 53,9 naspram 57,2 u skupini koja je primala placebo (p≤0,001).
English: Posology
Croatian: Tablica
English: The HAQ-DI scores were 1.1 at baseline vs. 0.84 at Week 25 in patients treated with pegloticase 8 mg every 2 weeks compared to 1.2 vs. 1.3 in the placebo group (p≤0.01).
Croatian: Rezultati HAQ-DI bili su 1,1 na početku naspram 0,84 u 25. tjednu u bolesnika liječenih peglotikazom 8 mg svaka dva tjedna u usporedbi s 1,2 naspram 1,3 u skupini koja je primala placebo (p≤0,01).
English: Metabolism and nutrition disorders Common: Hyperglycaemia Cardiac disorders
Croatian: Klasifikacija organskih sustava Nuspojava Poremećaji metabolizma i prehrane Često: hiperglikemija
English: The HAQ-PGA scores were 42.4 at baseline vs. 27.1 at Week 25 in patients treated with pegloticase 8 mg every 2 weeks compared to 51.6 vs. 53.4 in the placebo group (p≤0.001).
Croatian: Rezultati HAQ-PGA bili su 42,4 na početku naspram 27,1 u 25. tjednu u bolesnika liječenih peglotikazom 8 mg svaka dva tjedna u usporedbi s 51,6 naspram 53,4 u skupini koja je primala placebo (p≤0,001).
English: How KRYSTEXXA is administered
Croatian: Kako se KRYSTEXXA primjenjuje
English: Uncommon side effects: (may affect up to 1 in 100 people): worsening of a type of heart disease called congestive heart failure, skin infection, elevated potassium levels in the blood Frequency not known (cannot be estimated from available data): destruction of red blood cells If you get any side effects, talk to your doctor, pharmacist or nurse.
Croatian: Manje česte nuspojave: (mogu zahvatiti do 1 na 100 osoba): pogoršanje srčane bolesti zvane kongestivno zatajenje srca, infekcija kože, povišene razine kalija u krvi
English: KRYSTEXXA 8 mg concentrate for solution for infusion
Croatian: NAZIV GOTOVOG LIJEKA KRYSTEXXA 8 mg koncentrat za otopinu za infuziju
English: How to store KRYSTEXXA
Croatian: Kako čuvati lijek KRYSTEXXA
English: Allergic reactions may be more likely to occur in patients who weigh more than 100 kg. An increase in gout flares is frequently observed when starting KRYSTEXXA.
Croatian: Vjerojatnije je da će se alergijske reakcije pojaviti u bolesnika koji su teži od 100 kg.
English: 8 mg Pegloticase Every 2 Weeks (N = 62)
Croatian: Peglotikaza 8 mg svaka 2 tjedna
English: Disodium hydrogen phosphate dihydrate Sodium dihydrogen phosphate dihydrate Sodium chloride
Croatian: Natrijev dihidrogenfosfat dihidrat
English: Very common: Gout flare
Croatian: Manje često: hiperkalijemija
English: How to use KRYSTEXXA
Croatian: Kako primjenjivati lijek KRYSTEXXA
English: The mean PUA at baseline was 9.8 mg/dl. Seventy-one percent (71%) of patients had baseline tophi.
Croatian: Sedamdeset i jedan posto (71%) bolesnika imalo je tofe na početku.
English: INFORMATION IN BRAILLE
Croatian: KLINIČKI PODACI
English: Uncommon: Exacerbation of congestive heart failure
Croatian: Manje često: egzarcebacija kongestivnog zatajenja srca Poremećaji probavnog sustava Vrlo često: mučnina Često: povraćanje
English: Marketing Authorisation Holder
Croatian: Tablični sažetak nuspojava
English: Number of Patients with CR
Croatian: Broj bolesnika s dostupnim podacima
English: PHARMACEUTICAL FORM AND CONTENTS
Croatian: NAČIN PRIMJENE LIJEKA
English: Intravenous use
Croatian: U venu
English: Intraperitoneal use
Croatian: Insuman Infusat
English: vials (glass)
Croatian: 3 bočice
English: EU/1/97/030/202 Insuman Implantable
Croatian: Insuman Implantable
English: Solution for infusion
Croatian: Za primjenu u trbušnu šupljinu
English: The full EPAR for Copalia can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za lijek Copalia nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Copalia is taken by mouth as one tablet once a day with some water.
Croatian: Copalia se uzima peroralno kao jedna tableta jednom na dan s malo vode.
English: Other information about Copalia
Croatian: Ostale informacije o lijeku Copalia
English: The European Commission granted a marketing authorisation valid throughout the EU for Copalia on 16 January 2007.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Copalia na snazi u Europskoj uniji od 16. siječnja 2007.
English: This is a summary of the European public assessment report (EPAR) for Copalia.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Copalia.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Copalia.
Croatian: Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje za izdavanje odobrenja za stavljanje lijeka u promet i svoje preporuke o uvjetima za primjenu lijeka Copalia.
English: For more information about treatment with Copalia, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o terapiji lijekom Copalia pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: The company also presented evidence that the levels of amlodipine and valsartan in the blood were the same in people taking Copalia and people taking the separate medicines.
Croatian: Farmaceutska je tvrtka također dostavila dokaz da su koncentracije amlodipina i valsartana u krvi bile jednake u osoba koje su uzimale lijek Copalia i osoba koje su uzimale druge lijekove.
English: The most common side effects with Copalia (seen in between 1 and 10 patients in 100) are headache, nasopharyngitis (inflammation of the nose and throat), influenza (flu), hypokalaemia (low blood potassium levels), various types of oedema (swelling), fatigue (tiredness), flushing (reddening), asthenia (weakness) and hot flushes.
Croatian: Najčešće nuspojave lijeka Copalia (koje se mogu javiti u 1 do 10 osoba na 100 osoba) su glavobolja, nazofaringitis (upala nosa i grla), influenca (gripa), hipokalemija (mala koncentracija kalija u krvi), različiti tipovi edema (oticanje), iscrpljenost (umor), rumenilo (crvenilo), astenija (slabost) i napadaji vrućine.
English: What is the risk associated with Copalia?
Croatian: Koji su rizici povezani s lijekom Copalia?
English: The CHMP decided that Copalia's benefits are greater than its risks and recommended that it be given marketing authorisation.
Croatian: CHMP je odlučio da koristi od lijeka Copalia nadmašuju s njim povezane rizike te je preporučio izdavanje odobrenja za stavljanje lijeka u promet.
English: The dose of Copalia to be used depends on the doses of amlodipine or valsartan that the patient was taking before.
Croatian: Doza lijeka Copalia koja se primjenjuje ovisi o dozama amlodipina ili valsartana koje je bolesnik ranije uzimao.
English: What is Copalia?
Croatian: Što je Copalia?
English: Why has Copalia been approved?
Croatian: Zašto je Copalia odobrena?
English: Copalia must not be used in patients who have severe liver or bile problems, patients with certain heart problems and patients with severe hypotension (low blood pressure).
Croatian: Copalia se ne smije primjenjivati u bolesnika koji imaju ozbiljno oštećenje jetre ili probleme sa žući, u bolesnika s određenim srčanim tegobama i bolesnika s ozbiljnom hipotenzijom (niskim krvnim tlakom).
English: Copalia must not be used in patients who are hypersensitive (allergic) to amlodipine or other medicines in the ‘dihydropyridine derivatives' class, to valsartan, or to any of the other ingredients.
Croatian: Copalia se ne smije primjenjivati u bolesnika koji su preosjetljivi (alergični) na amlodipin ili druge lijekove iz klase „derivati dihidropiridina”, na valsartan ili bilo koju drugu pomoćnu tvar.
English: Copalia must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension) in patients with type 2 diabetes or in patients with moderate or severe kidney impairment.
Croatian: Copalia se također ne smije primjenjivati u kombinaciji s lijekovima koji sadrže aliskiren (koriste se također za liječenje esencijalne hipertenzije) u bolesnika s dijabetesom tipa 2 ili u bolesnika s umjerenim do ozbiljnim oštećenjem bubrega.
English: Copalia is a medicine that contains two active substances, amlodipine and valsartan.
Croatian: Copalia je lijek koji sadrži dvije djelatne tvari: amlodipin i valsartan.
English: What is Copalia used for?
Croatian: Za što se Copalia koristi?
English: For the full list of all side effects reported with Copalia, see the package leaflet.
Croatian: Potpuni popis nuspojava koje su zabilježene s lijekom Copalia potražite u uputi o lijeku.
English: What benefit has Copalia shown during the studies?
Croatian: Koje su koristi lijeka Copalia utvrđene u ispitivanjima?
English: How does Copalia work?
Croatian: Kako djeluje Copalia?
English: Copalia is used in patients who have essential hypertension (high blood pressure) that is not adequately controlled on either amlodipine or valsartan taken alone.
Croatian: Copalia se primjenjuje u bolesnika koji imaju esencijalnu hipertenziju (visoki krvni tlak), koji nije odgovarajuće kontroliran samo amlodipinom ili valsartanom. „Esencijalno” znači da hipertenzija nema očiti uzrok.
English: Copalia contains two active substances, amlodipine and valsartan.
Croatian: Copalia sadrži dvije djelatne tvari, amlodipin i valsartan.
English: How is Copalia used?
Croatian: Kako se Copalia primjenjuje?
English: How has Copalia been studied?
Croatian: Kako je lijek Copalia ispitivan?
English: Annex I List of the names, pharmaceutical form(s), strength(s) of the medicinal product(s), route(s) of administration, marketing authorisation holder(s) in the member states
Croatian: Popis naziva, farmaceutskog(ih) oblika, jačine(a) lijek(ov)a, put(ev)a primjene, nositelj(a) odobrenja u državama članicama
English: Sweden Mundipharma AB Mölndalsvägen 30B Göteborg
Croatian: Mundipharma AB Mölndalsvägen 30B Göteborg
English: Mundipharma AS Dicks vei 10B, 1366 Lysaker
Croatian: Norveška Mundipharma AS Dicks vei 10B, 1366
English: Oxycodone hydrochloride/ Naloxone hydrochloride dihydrate (Naloxone hydrochloride)
Croatian: Republika Češka oksikodonklorid/ naloksonklorid dihidrat (nalokson hidroklorid)
English: Mundipharma SAS 100, avenue de Suffren Paris
Croatian: Francuska Mundipharma SAS 100, avenue de Suffren Paris
English: Napp Pharmaceuticals Ltd. Cambridge Science Park Milton Road
Croatian: Cambridge Science Park Milton Road
English: Mundipharma SAS 100, avenue de Suffren, Paris
Croatian: Francuska Mundipharma SAS 100, avenue de Suffren, Paris
English: Mundipharma Pharmaceuticals Ltd. Millbank House, Arkle Road Sandyford, Dublin 18 Ireland
Croatian: Millbank House, Arkle Road Sandyford, Dublin 18 Ireland
English: Mundipharma Pharmaceuticals B.V.
Croatian: Nizozemska Mundipharma Pharmaceuticals B.V.
English: Mundipharma Pharmaceuticals, S.L.
Croatian: Mundipharma Pharmaceuticals Ltd.
English: Belgium Mundipharma Comm. VA Blarenberglaan 3C,
Croatian: VA Blarenberglaan 3C,
English: Targin 5 mg/2,5 mg tablety s prodlouženým uvolňováním
Croatian: 5 mg/2,5 mg tablety s prodlouženým uvolňováním
English: Mundipharma Pharmaceuticals Srl Via G. Serbelloni 4, Milano
Croatian: Mundipharma Pharmaceuticals Srl Via G.
English: Germany Mundipharma GmbH Mundipharma Str. 2
Croatian: Njemačka Mundipharma GmbH Mundipharma Str.
English: Targin 40 mg/20 mg tablety s prodlouženým uvolňováním
Croatian: 40 mg/20 mg tablety s prodlouženým uvolňováním
English: Luxembourg Mundipharma Comm. VA Blarenberglaan 3C
Croatian: VA Blarenberglaan 3C
English: C/ Bahía de Pollensa,11, Madrid
Croatian: Španjolska Mundipharma Pharmaceuticals, S.L. C/ Bahía de Pollensa,11, Madrid
English: C/ Bahía de Pollensa,11 Madrid
Croatian: Španjolska Mundipharma Pharmaceuticals, S.L. C/ Bahía de Pollensa,11 Madrid
English: Targin 20 mg/10 mg tablety s prodlouženým uvolňováním
Croatian: 20 mg/10 mg tablety s prodlouženým uvolňováním
English: Targin 10 mg/5 mg tablety s prodlouženým uvolňováním
Croatian: 10 mg/5 mg tablety s prodlouženým uvolňováním
English: Further information on Rizmoic can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/rizmoic
Croatian: Više informacija o lijeku Rizmoic nalazi se na internetskim stranicama Agencije:ema.europa.eu/medicines/human/EPAR/rizmoic
English: The recommended dose is one tablet once daily, which the patient can take with or without a laxative.
Croatian: Preporučena doza je jedna tableta jednom dnevno koju bolesnik može uzimati s laksativom ili bez njega.
English: Rizmoic is available as 200 microgram tablets.
Croatian: Rizmoic je dostupan u obliku tableta od 200 mikrograma.
English: The patient must stop taking Rizmoic when they are no longer taking an opioid.
Croatian: Bolesnik mora prestati uzimati Rizmoic kad prestane uzimati opioidni lijek.
English: What measures are being taken to ensure the safe and effective use of Rizmoic?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Rizmoic ?
English: Other information about Rizmoic
Croatian: Ostale informacije o lijeku Rizmoic
English: The European Medicines Agency therefore decided that Rizmoic's benefits are greater than its risks and it can be authorised for use in the EU.
Croatian: Europska agencija za lijekove stoga je zaključila da koristi od lijeka Rizmoic nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u EU-u.
English: Side effects reported with Rizmoic are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Rizmoic pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rizmoic have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Rizmoic nalaze se u sažetku opisa svojstava i u uputi o lijeku.
English: Constipation is the most common side effect of opioid pain medicines and many standard laxatives are not effective in treating the condition.
Croatian: Konstipacija je najčešća nuspojava opioidnih lijekova protiv bolova i brojni standardni laksativi nisu učinkoviti u liječenju te tegobe.
English: Because molecules of naldemedine were designed not be able to enter into the brain, the medicine does not block opioids from working on pain receptors in the brain and therefore does not interfere with pain relief.
Croatian: Kako su molekule naldemedina dizajnirane tako da ne ulaze u mozak, lijek ne sprječava djelovanje opioide na receptore za bol u mozgu i stoga ne ometa ublažavanje bolova.
English: As for all medicines, data on the use of Rizmoic are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Rizmoic kontinuirano se prate.
English: Why is Rizmoic authorised in the EU?
Croatian: Zašto je Rizmoic odobren u EU-u?
English: What is Rizmoic and what is it used for?
Croatian: Što je Rizmoic i za što se primjenjuje?
English: In patients with cancer, the most common side effects were diarrhoea (seen in more than 1 in 10 people) and abdominal pain (seen in up to 1 in 10 people).
Croatian: U bolesnika s rakom najčešće nuspojave bile su proljev (zabilježen u više od 1 na 10 osoba) i abdominalna bol (zabilježena u 1 na 10 osoba).
English: In two other studies, involving 307 patients taking opioids for cancer pain, 74% of patients taking Rizmoic for two weeks achieved the desired outcome compared with 36% of patients taking placebo.
Croatian: U druga dva ispitivanja na 307 bolesnika koji su uzimali opioide za ublažavanje bolova od raka, 74 % bolesnika koji su uzimali lijek Rizmoic tijekom dva tjedna postiglo je željeni rezultat, u usporedbi s 36 % bolesnika koji su uzimali placebo.
English: An overview of Rizmoic and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Rizmoic i zašto je odobren u EU-u
English: For more information about using Rizmoic, see the package leaflet or contact your doctor or pharmacist.
Croatian: Više informacija o primjeni lijeka Rizmoic pročitajte u uputi o lijeku, odnosno obratite se liječniku ili ljekarniku.
English: What are the risks associated with Rizmoic?
Croatian: Koji su rizici povezani s lijekom Rizmoic?
English: Rizmoic must not be used in patients with a blocked or perforated bowel or patients at high risk of bowel blockage.
Croatian: Rizmoic se ne smije primjenjivati u bolesnika s blokadom ili perforacijom crijeva, odnosno bolesnika kod kojih postoji visoki rizik od blokade crijeva.
English: In two of the studies, involving 1095 patients taking opioids for chronic (long-term) pain caused by a condition other than cancer, 50% of patients taking Rizmoic for 12 weeks achieved the desired outcome, compared with 34% of patients taking placebo.
Croatian: U dva ispitivanja na 1095 bolesnika koji su uzimali opioide za kroničnu (dugotrajnu) bol uzrokovanu stanjem koje nije rak, 50 % bolesnika koji su uzimali Rizmoic tijekom 12 tjedana postiglo je željeni rezultat, u usporedbi s 34 % bolesnika koji su uzimali placebo.
English: The most common side effects with Rizmoic in patients without cancer (which may affect up to 1 in 10 people) are abdominal pain (belly ache), diarrhoea, nausea and vomiting.
Croatian: Najčešće su nuspojave lijeka Rizmoic u bolesnika koji nemaju rak (koje se mogu javiti u 1 na 10 osoba) abdominalna bol (bol u trbuhu), proljev, mučnina i povraćanje.
English: The studies compared Rizmoic with placebo (a dummy treatment) to see if treatment would consistently increase the number of patients who can pass stools and allow them to do so at least 3 times a week during treatment.
Croatian: U ispitivanjima je lijek Rizmoic uspoređen s placebom (prividnim liječenjem) da se istraži ako bi se terapijom konzistentno povećao broj bolesnika koji imaju stolicu barem tri puta tjedno tijekom terapije.
English: The active substance in Rizmoic, naldemedine, works by attaching to and blocking receptors in the gut (mu-, delta- and kappa-opioid receptors), through which opioid medicines cause constipation.
Croatian: Djelatna tvar lijeka Rizmoic, naldemedin, djeluje vezivanjem na receptore u crijevima koje blokira (mu-, delta- i kappa-opioidni receptori), putem kojih opioidni lijekovi izazivaju konstipaciju.
English: Rizmoic has been shown to improve bowel movement in patients taking opioids pain medicines for long-term pain (including cancer pain).
Croatian: Pokazalo se da Rizmoic poboljšava rad crijeva u bolesnika koji uzimaju opioidne lijekove protiv bolova za dugoročnu bol (uključujući bol uzrokovanu rakom).
English: The majority of side effects in patients with or without cancer were mild to moderate.
Croatian: Većina nuspojava u bolesnika s rakom ili bez njega bila je blaga do umjerena.
English: Rizmoic can only be obtained with a prescription.
Croatian: Lijek Rizmoic izdaje se samo na liječnički recept.
English: Studies have shown that Rizmoic is effective at improving bowel movement in patients who are currently taking laxatives or had taken laxatives in the past.
Croatian: Ispitivanja su pokazala da je lijek Rizmoic djelotvoran pri poboljšanju rada crijeva u bolesnika koji uzimaju laksative ili su ih uzimali u prošlosti.
English: Rizmoic is a medicine for treating constipation caused by opioid pain relief medicines in patients who have previously been treated with a laxative (a medicine that triggers bowel movements).
Croatian: Rizmoic je lijek za konstipaciju izazvanu opioidnim lijekovima protiv bolova u bolesnika koji su prethodno primali terapiju laksativom (lijekom koji stimulira rad crijeva).
English: How does Rizmoic work?
Croatian: Kako djeluje Rizmoic?
English: What benefits of Rizmoic have been shown in studies?
Croatian: Koje su koristi od lijeka Rizmoic utvrđene u ispitivanjima?
English: Furthermore, the side effects of Rizmoic, which mainly affected the gut, were mostly mild or moderate.
Croatian: Nadalje, nuspojave lijeka Rizmoic, koje su se uglavnom javljale u crijevima, bile su blage do umjerene.
English: How is Rizmoic used?
Croatian: Kako se Rizmoic primjenjuje?
English: It contains the active substance naldemedine.
Croatian: Sadrži djelatnu tvar naldemedin.
English: as you may need medical attention.
Croatian: Vam mogla zatrebati medicinska pomoć.
English: ● Do not take a double dose to make up for a forgotten dose.
Croatian: • Nemojte uzeti dvostruku dozu kako biste nadoknadili zaboravljenu dozu.
English: To benefit from your medicine you should take it regularly every day at the same time of the day.
Croatian: Kako biste imali korist od ovog lijeka, trebate ga uzimati redovito svaki dan, u isto doba dana.
English: Once daily
Croatian: Jedanput na dan
English: In another case of a large overdose, the patient also survived and recovered.
Croatian: U drugom slučaju predoziranja velikom dozom bolesnik je također preživio, te se oporavio.
English: It belongs to a group of medicines known as anti-dementia medicines.
Croatian: Ubraja se u skupinu lijekova poznatih kao lijekovi protiv demencije.
English: If you are allergic to peanut or soya, do not take this medicinal product.
Croatian: Ako ste alergični na kikiriki ili soju, nemojte uzimati ovaj lijek.